Mortality in systemic lupus erythematosus.
Arthritis Rheum. 2006 Aug;54(8):2550-57.
Update on the treatment of lupus nephritis.
Kidney Int. 2006 Aug 23.
Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.
JAMA. 2006 Jul 26;296(4):397-402.
Azathioprine/methylprednisolone versus cyclophosphamide in proliferative lupus nephritis. A randomized controlled trial.
Kidney Int. 2006 Jul 5.
Safety and efficacy of influenza vaccination in systemic lupus erythematosus patients with quiescent disease.
Ann Rheum Dis. 2006 Jul;65(7):913-918.
Effects of Sleep Deprivation on the development of autoimmune disease in an experimental model of Systemic Lupus Erythematosus.
Am J Physiol Regul Integr Comp Physiol. 2006 Jun 29.
Association between serum total cholesterol level and renal outcome in systemic lupus erythematosus.
Arthritis Rheum. 2006 Jun 26;54(7):2211-2219.
A new approach to managing oral manifestations of Sjogren's syndrome and skin manifestations of lupus.
J Biochem Mol Biol. 2006 May 31;39(3):229-39.
Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.
Am J Transplant. 2006 May;6(5 Pt 1):859-66.
The Pediatric Rheumatology International Trials Organization/American College of Rheumatology provisional criteria for the evaluation of response to therapy in juvenile systemic lupus erythematosus: Prospective validation of the definition of improvement.
Arthritis Rheum. 2006 May 31;55(3):355-363.
Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study.
Arthritis Res Ther. 2006 May 5;8(3):R83.
B cell targeted therapies in autoimmune diseases.
J Rheumatol Suppl. 2006 May;77:24-8.
Mycophenylate mofetil: what role in the treatment of lupus?
Lupus. 2006;15(3):179-82.
Road to lupus therapy evinces plight of development
